Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Caladrius Bio (CLBS)

Caladrius Bio (CLBS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,324
  • Shares Outstanding, K 59,499
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,150 K
  • 60-Month Beta 1.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.75
Trade CLBS with:

Options Overview

Details
  • Implied Volatility 142.52%
  • Historical Volatility 26.11%
  • IV Percentile 35%
  • IV Rank 30.61%
  • IV High 350.79% on 10/30/20
  • IV Low 50.66% on 05/20/21
  • Put/Call Vol Ratio 0.01
  • Today's Volume 1,103
  • Volume Avg (30-Day) 1,155
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 33,848
  • Open Int (30-Day) 43,575

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.15
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.15
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +54.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3200 +3.03%
on 07/27/21
1.6400 -17.07%
on 06/29/21
-0.2800 (-17.07%)
since 06/28/21
3-Month
1.3200 +3.03%
on 07/27/21
1.6900 -19.53%
on 04/29/21
-0.2900 (-17.58%)
since 04/28/21
52-Week
1.2500 +8.80%
on 12/14/20
4.8900 -72.19%
on 01/20/21
-0.8100 (-37.33%)
since 07/28/20

Most Recent Stories

More News
Caladrius Biosciences to Present at Zooming with LD

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.3600 (+0.74%)
Caladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.3600 (+0.74%)
Caladrius Biosciences to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.3600 (+0.74%)
Caladrius Biosciences Announces Participation in Upcoming Conferences in June 2021

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.3600 (+0.74%)
New Strong Sell Stocks for May 27th

AFYA, BNL, CLBS, EKSO, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2021

LLY : 246.51 (+1.20%)
EKSO : 4.87 (+0.62%)
CLBS : 1.3600 (+0.74%)
AFYA : 23.83 (+4.15%)
BNL : 25.58 (-0.23%)
Caladrius Biosciences Receives $1.4 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.3600 (+0.74%)
Caladrius Biosciences, Inc. (CLBS) Reports Q1 Loss, Lags Revenue Estimates

Caladrius Biosciences, Inc. (CLBS) delivered earnings and revenue surprises of -111.11% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the...

CLBS : 1.3600 (+0.74%)
Caladrius Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides...

CLBS : 1.3600 (+0.74%)
Caladrius Biosciences, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Caladrius Biosciences, Inc. (NASDAQ:CLBS) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30...

CLBS : 1.3600 (+0.74%)
Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in May 2021

Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today...

CLBS : 1.3600 (+0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve...

See More

Key Turning Points

3rd Resistance Point 1.4333
2nd Resistance Point 1.4067
1st Resistance Point 1.3833
Last Price 1.3600
1st Support Level 1.3333
2nd Support Level 1.3067
3rd Support Level 1.2833

See More

52-Week High 4.8900
Fibonacci 61.8% 3.4995
Fibonacci 50% 3.0700
Fibonacci 38.2% 2.6405
Last Price 1.3600
52-Week Low 1.2500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar